BGT-002
BGT-002 (326E) is an orally active dual ACLY inhibitor and PPARα agonist. BGT-002 reduces lipogenesis by inhibiting synthesis and promoting efflux. BGT-002 demonstrated efficacy in ameliorating metabolic dysfunction-associated steatohepatitis (MASH) and improving hyperlipidemia in vivo. BGT-002 can be used for hypercholesterolemia and MASH research[1][2][3].
Product Specifications
CAS Number
2127387-94-2
Product Name Alternative
326E
UNSPSC
12352211
Target
ATP Citrate Lyase; PPAR
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Field of Research
Metabolic Disease
Smiles
CC(CCCC/C=C/CCCCCC(C)(C(O)=O)C)(C(O)=O)C
Molecular Formula
C19H34O4
Molecular Weight
326.47
References & Citations
[1]Xie Z, et al. The enedioic acid analog 326E alleviates metabolic dysfunction-associated steatohepatitis via dual targeting at ACLY and PPARα. Cell Metab. 2025 Nov 4;37 (11) :2149-2166.e9.|[2]Xie Z, et al. Development of the novel ACLY inhibitor 326E as a promising treatment for hypercholesterolemia. Acta Pharm Sin B. 2023 Feb;13 (2) :739-753.|[3]Zhu X, et al. Simultaneous determination of BGT-002 and its acyl glucuronide metabolite ZM326E-M2 in human plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. J Pharm Biomed Anal. 2024 Jun 15;243:116056.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PPARα
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
